Cytokine gene expression profile distinguishes CD4+/CD57+ T cells of the nodular lymphocyte predominance type of Hodgkin's lymphoma from their tonsillar counterparts

Journal of Pathology

Volumn 208, Issue 3, 2006, Pages 423-430

  Atayar, Çiǧdem ^a   Poppema, Sibrand ^a   Visser, Lydia ^a   van der Berg, Anke ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

CD4+ CD57+ T cells; Cytokines; Hodgkin's lymphoma; Nodular lymphocyte predominance type of Hodgkin's lymphoma; Progressive transformation of germinal centres; T cells

Indexed keywords

CD4 ANTIGEN; CD57 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; MESSENGER RNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ROSETTE FORMATION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TONSIL;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD57; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HODGKIN DISEASE; HUMANS; HYPERPLASIA; INTERFERON TYPE II; INTERLEUKIN-13; INTERLEUKIN-2; INTERLEUKIN-4; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; T-LYMPHOCYTES; TONSIL;

EID: 32244441798     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1894     Document Type: Article

References (34)

1. Kadin ME. Pathology of Hodgkin's disease. Curr Opin Oncol 1994;6:456-463.
2. Poppema S. Immunology of Hodgkin's disease. Baillières Clin Haematol 1996;9:447-457.
3. Harris NL. Hodgkin's lymphomas: classification, diagnosis, and grading. Semin Hematol 1999;36:220-232.
4. Poppema S. The nature of the lymphocytes surrounding Reed-Sternberg cells in nodular lymphocyte predominance and in other types of Hodgkin's disease. Am J Pathol 1989;135:351-357.
5. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin's lymphoma. Blood 2002;99:4283-4297.
6. Falini B, Bigerna B, Pasqualucci L, Fizzotti M, Martelli MF, Pileri S, et al. Distinctive expression pattern of the BCL-6 protein in nodular lymphocyte predominance Hodgkin's disease. Blood 1996;87:465-471.
7. Bowen MB, Butch AW, Parvin CA, Levine A, Nahm MH. Germinal center T cells are distinct helper-inducer T cells. Hum Immunol 1991;31:67-75.
8. Cattoretti G, Chang CC, Cechova K, Zhang J, Ye BH, Falini B, et al. BCL-6 protein is expressed in germinal-center B cells. Blood 1995;86:45-53.
9. Chan WC. Cellular origin of nodular lymphocyte-predominant Hodgkin's lymphoma: immunophenotypic and molecular studies. Semin Hematol 1999;36:242-252.
10. Dargent JL, Schandene L, Kornreich A, Lespagnard L, Cochaux P, Jagodzinski R, et al. Nature of the T lymphocytes in lymphocyte predominance Hodgkin's disease. Leuk Lymphoma 1997;24:545-551.
11. Nguyen PL, Ferry JA, Harris NL. Progressive transformation of germinal centers and nodular lymphocyte predominance Hodgkin's disease: a comparative immunohistochemical study. Am J Surg Pathol 1999;23:27-33.
12. Hansmann ML, Fellbaum C, Hui PK, Moubayed P. Progressive transformation of germinal centers with and without association to Hodgkin's disease. Am J Clin Pathol 1990;93:219-226.
13. Atayar C, Poppema S, Blokzijl T, Harms G, Boot M, van den Berg A. Expression of the T cell transcription factors, GATA-3 and T-beta, in the neoplastic cells of Hodgkin's lymphomas. Am J Pathol 2005;166:127-134.
14. Timens W, Visser L, Poppema S. Nodular lymphocyte predominance type of Hodgkin's disease is a germinal center lymphoma. Lab Invest 1986;54:457-461.
15. Poppema S, Atayar C. Nodular lymphocyte predominance type of Hodgkin's lymphoma. In Diagnostic Hematopathology, Jaffe ES (ed.). Harcourt Health Sciences: Oxford; 2006; (in press).
16. Gruss HJ, Dower SK. Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood 1995;85:3378-3404.
17. Elser B, Lohoff M, Kock S, Giaisi M, Kirchhoff S, Krammer PH, et al. IFN-γ represses IL-4 expression via IRF-1 and IRF-2. Immunity 2002;17:703-712.
18. + T cells. Blood 2003;101:2711-2720.
19. Levings MK, Bacchetta R, Schulz U, Roncarolo MG. The role of IL-10 and TGF-β in the differentiation and effector function of T regulatory cells. Int Arch Allergy Immunol 2002;129:263-276.
20. Levings MK, Sangregorio R, Galbiati F, Squadrone S, de Waal MR, Roncarolo MG. IFN-α and IL-10 induce the differentiation of human type 1 T regulatory cells. J Immunol 2001;166:5530-5539.
21. + T cell subset inhibits antigen-specific T cell responses and prevents colitis. Nature 1997; 389:737-742.
22. Gottlieb D. Cytokine manipulation of the immune response in the treatment of human acute leukaemia. Curr Pharm Des 2002;8:419-431.
23. Rush JS, Hodgkin PD. B cells activated via CD40 and IL-4 undergo a division burst but require continued stimulation to maintain division, survival and differentiation. Eur J Immunol 2001;31:1150-1159.
24. Nelms K, Huang H, Ryan J, Keegan A, Paul WE. Interleukin-4 receptor signalling mechanisms and their biological significance. Adv Exp Med Biol 1998;452:37-43.
25. + germinal center T cells are the major helpers for GC-B cells and induce class switch recombination. BMC Immunol 2005;6:3.
26. Zhou C, Saxon A, Zhang K. Human activation-induced cytidine deaminase is induced by IL-4 and negatively regulated by CD45: implication of CD45 as a Janus kinase phosphatase in antibody diversification. J Immunol 2003;170:1887-1893.
27. Greiner A, Tobollik S, Buettner M, Jungnickel B, Herrmann K, Kremmer E, et al. Differential expression of activation-induced cytidine deaminase (AID) in nodular lymphocyte-predominant and classical Hodgkin's lymphoma. J Pathol 2005;205:541-547.
28. Braeuninger A, Kuppers R, Strickler JG, Wacker HH, Rajewsky K, Hansmann ML. Hodgkin and Reed-Sternberg cells in lymphocyte-predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proc Natl Acad Sci USA 1997;94:9337-9342.
29. - precursors by differentiation occurring in late immune responses. Eur J Immunol 1994;24:1503-1511.
30. Kapp U, Yeh WC, Patterson B, Elia AJ, Kagi D, Ho A, et al. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med 1999;189:1939-1946.
31. Ohshima K, Akaiwa M, Umeshita R, Suzumiya J, Izuhara K, Kikuchi M. Interleukin-13 and interleukin-13 receptor in Hodgkin's disease: possible autocrine mechanism and involvement in fibrosis. Histopathology 2001;38:368-375.
32. Skinnider BF, Elia AJ, Gascoyne RD, Trumper LH, von Bonin F, Kapp U, et al. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin's lymphoma. Blood 2001;97:250-255.
33. Minty A, Chalon P, Derocq JM, Dumont X, Guillemot JC, Kaghad M, et al. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 1993;362:248-250.
34. Zurawski G, de Vries JE. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 1994;15:19-26.